Lariam (Mefloquine Hydrochloride)

Mefloquine interferes with the malaria parasite’s ability to detoxify heme and disrupts its cell membrane function, leading to accumulation of toxic substances inside the parasite and ultimately causing parasite death.

The specific dose and regimen of Lariam are determined by the prescribing healthcare professional based on the indication, patient weight, age, and regional resistance patterns. Patients should follow the prescriber’s instructions exactly.

Safety of mefloquine in pregnancy and lactation has not been fully established. It should only be used when the potential benefits justify the potential risks, and the decision must be made by a qualified healthcare provider.

To order Lariam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lariam (mefloquine) is a quinoline antimalarial offering weekly prophylaxis and single‑dose treatment, whereas alternatives such as atovaquone‑proguanil or doxycycline require daily dosing. Choice depends on resistance patterns, patient tolerance, and specific travel or treatment needs.

Lariam should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lariam is taken orally, usually with a full glass of water. For prophylaxis, it is started one to two weeks before travel, taken weekly during exposure, and continued for four weeks after leaving the endemic area. For treatment, the regimen is prescribed by a clinician.

Serious risks include neuropsychiatric effects such as severe anxiety, depression, psychosis, seizures, and rare cardiac arrhythmias. Patients should seek immediate medical attention if they experience mood changes, hallucinations, or heart rhythm disturbances.

Lariam is contraindicated in individuals with a history of severe neuropsychiatric disorders, known hypersensitivity to mefloquine or related compounds, and in patients with significant cardiac conduction abnormalities. Pregnant women should only use it when clearly indicated by a healthcare professional.